We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

T2 Biosystems Ink R&D Collaboration with Bayer

T2 Biosystems Ink R&D Collaboration with Bayer

T2 Biosystems Ink R&D Collaboration with Bayer

T2 Biosystems Ink R&D Collaboration with Bayer

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "T2 Biosystems Ink R&D Collaboration with Bayer"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

T2 Biosystems, Inc. has signed a multi-year agreement to provide T2 Biosystems’ T2 Magnetic Resonance technology platform, or T2MR®, for Bayer’s research and development efforts in blood coagulation disorders. This collaboration will develop tools and evaluate assays to help drive drug discovery and biomarker research for select Bayer hemostasis-related programs.

The sensitivity of T2MR in blood coagulation (hemostasis) research allows for the rapid and comprehensive monitoring of drug side effects in animal models and patients.

"We are very enthusiastic about our collaboration with Bayer and the important validation it represents for our T2MR technology in the field of hemostasis," said John McDonough, chief executive officer of T2 Biosystems. "Together with Bayer, we look forward to continuing the exploration of the clinical potential of our platform to provide improved patient care in this area of significant unmet need.”

The companies have been working together for the last year and recently extended the collaboration to include a number of pre-clinical and early clinical programs. This collaboration will enable T2 Biosystems and Bayer to evaluate the T2MR technology with the hemostasis drug discovery and development efforts at Bayer.

About T2MR

T2MR is a diagnostic detection method utilizing miniaturized magnetic resonance technology that measures how water molecules react in the presence of magnetic fields. The T2MR technology platform offers a fast, simple and sensitive alternative to existing diagnostic methodologies. T2MR technology powers all of the diagnostic innovation at T2 Biosystems and enables the detection of a variety of different targets including molecular targets, immunodiagnostics and a broad range of hemostasis measurements. Additionally, by incorporating the T2MR diagnostic platform into clinical trials, drug developers have the potential to dramatically enrich patient populations, which could result in decreased timelines and reduced cost of trials. Another key benefit to drug developers is the potential to have patients diagnosed rapidly enough to avoid courses of empiric therapy prior to the administration of the investigational drug, which could help to achieve clinical superiority.

About T2MR in Hemostasis 

The first stage of wound healing, hemostasis, is a complex interaction of proteins and biochemical signals regulating the balance between bleeding and blood clotting. Patients with impaired hemostasis are either unable to promote the formation of blood clots to stabilize excessive bleeding or are hypercoaguable, with clots forming when they are not medically necessary. For hemostasis measurements, T2MR is highly sensitive to changes in viscosity in a blood sample (such as clot formation, stabilization or dissipation), which alter the magnetic resonance signal and enable identification of clinically relevant hemostasis changes. The T2MR-based hemostasis platform is being developed to provide a wide range of hemostasis diagnostics, including measurements of platelet activity, fibrinolysis and clotting time, directly from a blood volume not more than a finger stick amount of blood sample.